The decision follows results from an ongoing open-label Phase 1b study in adults with active or stable non-segmental vitiligo (NSV), a chronic autoimmune disease that causes loss of skin pigmentation. Teva said TEV-‘408 improved pigmentation and has been well-tolerated, with no safety signals reported to date.
Early Data Show Skin Pigmentation Improvements
At enrollment, 66% of participants had vitiligo affecting more than 10% of their body surface area.
Among evaluable patients at Week 24, nearly 75% reported improvements in facial vitiligo, while 50% rated their condition as “much improved” or “very much improved.”
Teva said 42% achieved F-VASI50 (at least a 50% improvement in facial vitiligo), 21% reached F-VASI75, 55% reported improvement in total body disease, and 7% achieved T-VASI50.
